Abstracts
Submission rules
Abstract submission fee
Content rules
Submission rules
1. Abstracts will not be accepted unless they are submitted online via
the online abstract submission system before midnight (GMT), Sunday
4th July 2010. Late abstracts will NOT be accepted. Abstracts submitted by
post, fax or email will not be considered.
2. All abstracts should be written, submitted and presented in
English with a maximum word count of 250 words (not including the abstract
title, authors and institutions).
3. All correspondence will be sent to the submitting author only.
It is the responsibility of the submitting author to forward any relevant
correspondence to the presenting author.
4. Each author is permitted to present once (not including invited
lectures).
5. Authors will be notified in writing in July 2010 whether or
not their abstract has been approved by the Scientific Advisory Committee
(SAC). The decision of the SAC is final and no correspondence will be
entered into.
6. Once an abstract has been approved, the presenting author
must register for the Congress for final acceptance. Abstracts will only
receive final acceptance if the presenting author has registered for the
entire Congress. Day registrations will not be permitted.
7. All presenting authors are expected to attend the congress.
Non-registered presenting authors may be excluded from publication in
the congress final programme.
8. Instructions for both platform and poster presentations will
be available on the congress website. Abstracts selected for oral presentations
may use either Microsoft PowerPoint (PC Format) or standard VHS video
only.
Abstract submission fee
- An abstract submission fee of US$ 40 must be paid at the time of abstract submission. This non-refundable fee will be automatically deducted from the congress registration fee.
- Abstract submitted without the fee will not be reviewed by the Scientific Advisory Committee.
- Abstract authors whose full registration fee will be covered
by a third party will be reimbursed the abstract submission
fee after the congress.
Content rules
1. Abstract submitters should ensure that the version sent is the final
one, changes will not be permitted.
2. Institution information should be provided for all authors.
Including institution, city, state/province and country but excluding
department, division, laboratory, etc.
3. Category: please select the category from the list displayed in the
drop down menu.
-
1. Basic Sciences
2. Neurobiology
3. Genetics
4. Translational Research
5. Adult Epileptology
6. Women and Pregnancy
7. Status Epilepticus
8. Epidemiology
9. Prognosis
10. Pediatric Epileptology
11. AED Issues
12. Clinical Neurophysiology
13. EEG
14. Seizure Semiology
15. Psychiatry
16. Neuropsychology
17. Social Issues
18. Surgery
19. Neuroimaging
20. Others
4. Abstracts should be structured in 4 sections:
1. Purpose 2. Method 3. Results 4. Conclusion
The "Purpose" section should indicate the objectives of the work being presented. The "Method" section should describe study material or subjects (e.g. number and type of patients), intervention and evaluation procedures. The "Results" section should summarise the main findings. Wherever possible, give numerical values, including means with SD or SEM, and statistical significance or confidence intervals. The "Conclusion" section should state briefly the conclusions reached in the work.
5. Figures, tables and other illustrations can not be included.
6. If the work was supported by funds provided by a commercial organisation this should be stated in a short acknowledgment at the end of the abstract. Other sources of funding may be acknowledged in the same way.
7. Submission of abstracts describing data that have previously been published in any scientific journal is not permitted.
8. Multiple submissions of abstracts describing different components of the same study is not appropriate. All findings generated from the same study should be included in a single abstract.
9. Abstracts containing single case reports will not usually be accepted, unless the report is of outstanding scientific or clinical interest because of the uniqueness of the findings or the sophistication of the investigations.
10. Abstracts containing data considered to be insufficiently informative will not be accepted.
11. Authors should use a concise title that indicates the content of the abstract. The title should not exceed 240 characters. Abbreviations should be avoided in the title.
12. For intervention studies (for example, therapeutic trials), type of design (prospective or retrospective, controlled or uncontrolled, randomised or observational, open vs. single-blind vs. double-blind), dosages, assessment methods and duration of follow-up should be specified.
13. Non-proprietary names of drugs must be used throughout. If results are considered to be specific for a given proprietary product (for example, bio-equivalence studies), the non-proprietary name must still be used, followed by the proprietary name and the name of the manufacturers in brackets.
14. Abbreviations should be used sparingly. For words that are abbreviated, use the whole term the first time, followed by the standard abbreviation in parenthesis. For anti-epileptic drugs, standard abbreviations are those published in Epilepsia 1993; 34:1151.
15. References should be used sparingly. They should be included within the text in brackets. For journals, mention first author "et al" followed by the name of the journal as abbreviated in the Index Medicus, year, volume number and inclusive pages (i.e. Hardus P et al. Epilepsia 2001;42:262-267.). For book chapters, give first author "et al", editor, title, publisher, city of publication, year and inclusive pages (i.e. Levy RH et al. In: Levy RH et al, Antiepileptic Drugs. Lippincott-Raven, 1996;13-30.).
16. Submission of an abstract automatically implies acknowledgment that the work described was conducted in accordance with current ethical standards and regulations in biomedical research. Failure to adhere to these standards will result in rejection of the abstract.
